Wed. 28 Feb 2024, 4:33pm ET
Benzinga
Earnings, News
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.37) by 2.19 percent. This is a 22.94 percent decrease over losses of $(1.09) per share from the same period last year.